Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · October 15, 2022

Association Between SGLT2 Inhibitor Use and the Short-Term Risk of Bladder Cancer

Diabetes Care

 

Additional Info

Diabetes Care
Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study
Diabetes Care 2022 Sep 28;[EPub Ahead of Print], D Abrahami, H Tesfaye, H Yin, S Vine, B Hicks, OHY Yu, L Campeau, RW Platt, S Schneeweiss, E Patorno, L Azoulay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading